Back to Search
CARLOS DECASTRO, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1912080169IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
33980(NC)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL SCHOOL AT DALLAS
Class of 1985
Research & Publications (19)
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
PMID 19452542·Cancer·2009
8-other
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
PMID 18766965·Leuk Lymphoma·2008
3-trial
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
PMID 17654680·Am J Hematol·2007
8-other
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
PMID 17228020·J Clin Oncol·2007
3-trial
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.
PMID 15453927·Clin Lymphoma·2004
8-other
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
PMID 15160345·Cancer·2004
3-trial
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.
PMID 15118546·Medicine (Baltimore)·2004
4-observational
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.
PMID 15100153·Blood·2004
3-trial
Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
PMID 14556684·Clin Lymphoma·2003
5-case
High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series.
PMID 12879438·Am J Hematol·2003
8-other
Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria.
PMID 12706380·Mol Genet Metab·2003
8-other
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.
PMID 12576433·Clin Cancer Res·2003
3-trial
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
PMID 12148879·Leuk Lymphoma·2002
8-other
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
PMID 12089230·J Clin Oncol·2002
3-trial
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
PMID 12011121·J Clin Oncol·2002
3-trial
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
PMID 12011120·J Clin Oncol·2002
3-trial
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
PMID 11821447·J Clin Oncol·2002
3-trial
Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes.
PMID 11750098·Exp Hematol·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- DUKE UNIVERSITY MEDICAL CTR
DURHAM, NC 27710 - Phone
- (919) 620-4467
Quick Facts
- NPI
- 1912080169
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Publications
- 19
Are you this provider?
Claim Your Profile